BioCardia, Inc. (BCDA) Stock Price & Analysis
BioCardia, Inc. (BCDA) closed at USD 0.92 on Friday, October 23, 2026, down 0.83% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.92; the Oct 23, 2026 session ranged USD 0.91–0.95 on volume of 40,281 shares. Market capitalization is —, with a 52-week range of USD 0.75–1.8 (NCM). Source: Nexqual, retrieved October 24, 2026 at 12:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BCDA.md
Key facts (BCDA)
- Total return with dividends: 1Y -33.8% vs S&P 500 +13.4%; 5Y -97.8% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BCDA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.4M | $477K | $58K | $0K | — |
| Gross profit | $1.0M | — | — | — | — | — |
| Operating income | -$12.6M | -$11.9M | -$11.6M | -$8.0M | -$8.3M | -$7.4M |
| Net income | -$12.6M | -$11.9M | -$11.6M | -$7.9M | -$8.2M | -$7.3M |
| EPS (diluted) | -$11.25 | — | — | — | — | — |
| Free cash flow | -$10.5M | -$10.6M | -$10.0M | -$7.9M | -$7.4M | -$7.6M |
| Gross margin | 100.0% | — | — | — | — | — |
| Operating margin | -1244.3% | -880.3% | -2441.1% | -13794.8% | — | — |
| Net margin | -1243.6% | -880.7% | -2425.8% | -13700.0% | — | — |
| Revenue growth | +600.0% | +33.2% | -64.7% | -87.8% | -100.0% | — |
| Cash + short-term investments | $12.9M | $7.4M | $1.1M | $2.4M | $2.5M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BCDA)
Analysts (BCDA)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-24 | HC Wainwright & Co. | Reiterated | Buy | $25 |
Total return (dividends reinvested) (BCDA)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -33.8% | -97.8% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -33.9% | -53.5% |
| Volatility (annualized) | 68.1% | 94.8% |
| Max drawdown | -47.6% (Dec 2025→Jul 2026) | -98.0% (Oct 2021→Jul 2026) |
BCDA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Biomet Biologics | “The CardiAMP autologous cell processing platform is manufactured for us by our partner Biomet Biologics, LLC.” |
| Supplier | NASDAQ Stock Market | “Further, delisting from the Nasdaq could also have other negative effects, including potential loss of confidence by partners, lenders, suppliers and employees and could also trigger various defaults under our financing arrangements and other outstanding agreements.” |
| Partner | Biomet Biologic | “We are a party to a license and distribution agreement with Biomet Biologics, LLC under which we obtained an exclusive, nontransferable, worldwide distribution right, patent license and trademark license to Biomet Biologic, LLC's point of care cell processing platform.” |
| Partner | Maryland Technology Development | “In June 2016, we entered into a grant agreement with Maryland Technology Development Corporation (TEDCO).” |
| Competitor | Moderna (MRNA) | “The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market, including AstraZeneca, Bayer, Blue Rock Therapeutics, Bristol-Myers Squibb, Lisata Therapeutics, Capricor Therapeutics, Celixir, Celyad, Daiichi Sankyo, Fuji Film, Mesoblast, Moderna, Orizuru Therapeutics, Sana Biotechnology, Takeda Pharmaceuticals, Tenaya Therapeutics, Terumo, Vericel Cor…” |
Quoted from the company's 10-K filed Mar 24, 2026.
BCDA customer concentration
In the period ended Dec 31, 2024, 3 direct customers each accounted for at least 10% (62%, 22%, 16%) of revenue, per the company's 10-K filed Mar 24, 2026. The company does not name them.
BCDA company outlook (results filed Aug 12, 2026)
- “As is customary, BioCardia provided draft minutes to FDA on May 12th with expectation that formal revised minutes from FDA or notification that the minutes are accepted and final would be provided on or before June 12 th .”
- “These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.”
Quoted word-for-word from the SEC 8-K results press release.
BCDA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.15 | $-0.17 | -11.8% | $0 | 1 |
| Next quarter (ends Dec 2026) | $-0.21 | $-0.18 | +16.7% | $0 | 1 |
| Current fiscal year (ends Dec 2026) | $-0.71 | $-0.71 | +0.0% | $0 | 1 |
| Next fiscal year (ends Dec 2027) | $-0.58 | $-0.56 | +3.6% | $0 | 1 |
Key Statistics (as of October 24, 2026 at 12:39 UTC)
| Price | USD 0.92 |
|---|---|
| Change | ▼ 0.83% (down) |
| Previous Close | USD 0.92 |
| Open | USD 0.92 |
| Day Range | USD 0.91 – 0.95 |
| 52-Week Range | USD 0.75 – 1.8 |
| Volume | 40,281 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (BCDA)
Nexqual's technical model rates BCDA "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 12:39 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.65 (neutral) |
| vs SMA50 | Below (USD 1.06) |
| MACD | -0.03 (negative) |
Earnings (BCDA)
| EPS Estimate | USD -0.15 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.19 ▲ beat |
| 2026-03-31 | USD -0.21 vs est -0.17 ▼ miss |
| 2025-12-31 | USD -0.06 vs est -0.2 ▲ beat |
| 2025-09-30 | USD -0.24 vs est -0.25 ▲ beat |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Financials & Fundamentals (BCDA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -1803.19% |
| Debt / Equity | 0.11 |
| Current Ratio | 2.09 |
| Total Cash | $4.12M |
| Total Debt | $293,000 |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Ownership (BCDA)
| Insider Ownership | +17.93% |
|---|---|
| Institutional Ownership | +14.78% |
| Shares Outstanding | 15.14M |
| Float | 12.26M |
| Short % of Float | +4.66% |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
From BioCardia, Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADIL | Adial Pharmaceuticals, Inc | USD 3.92 | ▼ 7.11% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.47 | ▼ 8.02% |
| NMAD | Nomad Power Solutions, Inc. | USD 3.81 | ▲ 5.83% |
| PHIO | Phio Pharmaceuticals Corp. | USD 0.85 | ▼ 2.36% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 100% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 12:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt